RP-A501

Rocket Pharmaceuticals Inc. · Phase 1 active Biologic

At a glance

Generic name	RP-A501
Sponsor	Rocket Pharmaceuticals Inc.
Modality	Biologic
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Gene Therapy Study of RP-A501 in Male Patients With Danon Disease (PHASE2)
Gene Therapy for Male Patients With Danon Disease (DD) Using RP-A501; AAV9.LAMP2B (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

RP-A501 CI brief — competitive landscape report
RP-A501 updates RSS · CI watch RSS
Rocket Pharmaceuticals Inc. portfolio CI